← Eichor
Condition: Locally Advanced Or Metastatic Er Her2 Breast Cancer Synced from ClinicalTrials.gov · July 30, 2026

Recruiting studies: Locally Advanced Or Metastatic Er Her2 Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Gire
Phase 1 · 4 location(s) · Genentech, Inc. · NCT07214662Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Adva
Phase 3 · 224 location(s) · LeonaBio · NCT05696626Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
Phase 2 · 11 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT04965766A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants Wi
Phase 1 · 11 location(s) · IDEAYA Biosciences · NCT07540572A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestran
Phase 1/Phase 2 · 52 location(s) · Genentech, Inc. · NCT07100106A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
Phase 3 · 2 location(s) · InventisBio Co., Ltd · NCT06954961A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Phase 1/Phase 2 · 1 location(s) · Forward Pharmaceuticals Co., Ltd. · NCT07002177Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/
Phase 1/Phase 2 · 14 location(s) · Ellipses Pharma · NCT05573126Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+,
Phase 1 · 16 location(s) · Olema Pharmaceuticals, Inc. · NCT05508906A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Brea
Phase 3 · 60 location(s) · Jiangsu Simcere Pharmaceutical Co., Ltd. · NCT06680921Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer
Phase N/A · 3 location(s) · iOMEDICO AG · NCT07563595A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recu
Phase 2/Phase 3 · 295 location(s) · Bristol-Myers Squibb · NCT06926868A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
Phase 1/Phase 2 · 22 location(s) · Forward Pharmaceuticals Co., Ltd. · NCT06064812A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive,
Phase 3 · 202 location(s) · Pfizer · NCT07062965Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Phase 2 · 44 location(s) · Pfizer · NCT04606446The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/Phase 2 · 77 location(s) · PMV Pharmaceuticals, Inc · NCT04585750
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.